<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069729</url>
  </required_header>
  <id_info>
    <org_study_id>R43DK104578-01</org_study_id>
    <nct_id>NCT03069729</nct_id>
  </id_info>
  <brief_title>Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)</brief_title>
  <official_title>Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VisionQuest Biomedical LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VisionQuest Biomedical LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to develop better tools for diagnosing illness of the feet and&#xD;
      legs of people who have diabetes. Investigators will use thermal videos of the foot to aid in&#xD;
      the refinement of a system designed to detect signs of diabetic peripheral neuropathy (DPN).&#xD;
      The team of investigators will also look at diabetic eye disease and how it might relate to&#xD;
      diabetic foot disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study focuses on further development and testing of a microvascular functional imaging&#xD;
      system, a computer-based system for screening thermal video images, designed to detect&#xD;
      biomarkers of diabetic peripheral neuropathy (DPN). Additionally, severity levels of diabetic&#xD;
      retinopathy (DR) will be compared with those of DPN.&#xD;
&#xD;
      All participants in this study will undergo foot exams, thermal imaging of the foot, and&#xD;
      standard retinal imaging. These non-invasive assessments will be performed at an initial&#xD;
      study visit. Some of the participants will be offered additional study visits. One of the&#xD;
      additional visits involves a standard nerve conduction velocity assessment by a neurologist,&#xD;
      the other involves a DPN exam by a podiatrist.&#xD;
&#xD;
      Portions of the study take place at University of New Mexico Health Sciences Center (UNM&#xD;
      HSC). The research utilizes services of the Clinical Translational Science Center (CTSC).&#xD;
&#xD;
      The study is approved by University of New Mexico Health Sciences Center's Human Research&#xD;
      Review Committee (HRRC), which coordinates and supports the activities of the three federally&#xD;
      mandated Human Research Review Committees (HRRCs) responsible for reviewing and approving all&#xD;
      human research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pattern of thermal recovery</measure>
    <time_frame>24 months</time_frame>
    <description>The thermal recovery pattern after cold provocation will be different for each group studied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of DPN severity levels and DR severity levels</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation between severity levels of DR and DPN will be determined.&#xD;
The severity level of DR will be assessed by qualified retinal image readers. Level of severity will be assigned, based on the International Clinical Diabetic Retinopathy Disease Severity Scale, into 5 levels:&#xD;
No apparent retinopathy&#xD;
Mild nonproliferative diabetic retinopathy&#xD;
Moderate nonproliferative diabetic retinopathy&#xD;
Severe nonproliferative diabetic retinopathy&#xD;
Proliferative diabetic retinopathy&#xD;
The severity of DPN will be graded by utilizing data from assessments from a DPN exam performed by an experienced podiatrist, Nerve Conduction Velocity (NCV) test performed by a neurologist, and assessments performed by technicians. Data utilized will include:&#xD;
NVC results&#xD;
Vibration threshold, reported in seconds&#xD;
Monofilament test of protective sensation</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">331</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <condition>Diabetic Foot</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>non-diabetic; no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics without DPN</arm_group_label>
    <description>diabetics without DPN; no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics with DPN</arm_group_label>
    <description>diabetics with DPN; no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Diabetics with DPN</arm_group_label>
    <arm_group_label>Diabetics without DPN</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of diabetic and non-diabetic individuals who are otherwise&#xD;
        healthy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Must be non-diabetic or diagnosed as diabetic for at least 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        history of chemotherapy&#xD;
&#xD;
          -  surgery below the knee within the last 2 years&#xD;
&#xD;
          -  fractures below the know within the last 2 years&#xD;
&#xD;
          -  history of stroke&#xD;
&#xD;
          -  body mass index (BMI) greater than 35&#xD;
&#xD;
          -  history of heart failure&#xD;
&#xD;
          -  peacemaker or implantable cardiovascular defibrillator&#xD;
&#xD;
          -  high blood pressure (over 180/100)&#xD;
&#xD;
          -  end-stage renal (kidney) disease or renal (kidney) transplant&#xD;
&#xD;
          -  peripheral edema greater than 2+ (swelling of the feet or hands)&#xD;
&#xD;
          -  diabetic foot ulcers&#xD;
&#xD;
          -  foot sores&#xD;
&#xD;
          -  Raynaud's phenomenon&#xD;
&#xD;
          -  tobacco use within the last month.&#xD;
&#xD;
          -  treatment with glucocorticoids, including:&#xD;
&#xD;
               -  beclomethasone&#xD;
&#xD;
               -  betamethasone&#xD;
&#xD;
               -  budesonide&#xD;
&#xD;
               -  cortisone&#xD;
&#xD;
               -  dexamethasone&#xD;
&#xD;
               -  hydrocortisone&#xD;
&#xD;
               -  methylprednisolone&#xD;
&#xD;
               -  prednisolone&#xD;
&#xD;
               -  prednisone&#xD;
&#xD;
               -  triamcinolone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Soliz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VisionQuest Biomedical LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VisionQuest Biomedical LLC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

